These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30289950)

  • 1. Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.
    Manichaikul A; Wang XQ; Li L; Erdmann J; Lettre G; Bis JC; Waterworth D; Cushman M; Jenny NS; Post WS; Palmas W; Tsai MY; Wallentin L; White H; Schunkert H; O'Donnell CJ; Herrington DM; Rich SS; O'Donoghue ML; Rodriguez A
    PLoS One; 2018; 13(10):e0204352. PubMed ID: 30289950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of SCARB1 variants with subclinical atherosclerosis and incident cardiovascular disease: the multi-ethnic study of atherosclerosis.
    Manichaikul A; Naj AC; Herrington D; Post W; Rich SS; Rodriguez A
    Arterioscler Thromb Vasc Biol; 2012 Aug; 32(8):1991-9. PubMed ID: 22628436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.
    Garg PK; McClelland RL; Jenny NS; Criqui MH; Greenland P; Rosenson RS; Siscovick DS; Jorgensen N; Cushman M
    Atherosclerosis; 2015 Jul; 241(1):176-82. PubMed ID: 26004387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
    Yeo A; Li L; Warren L; Aponte J; Fraser D; King K; Johansson K; Barnes A; MacPhee C; Davies R; Chissoe S; Tarka E; O'Donoghue ML; White HD; Wallentin L; Waterworth D
    PLoS One; 2017; 12(7):e0182115. PubMed ID: 28753643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
    Wallentin L; Held C; Armstrong PW; Cannon CP; Davies RY; Granger CB; Hagström E; Harrington RA; Hochman JS; Koenig W; Krug-Gourley S; Mohler ER; Siegbahn A; Tarka E; Steg PG; Stewart RA; Weiss R; Östlund O; White HD;
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27329448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein-associated phospholipase A
    Öngen B; Kalkan Uçar S; Levent E; Azarsız E; Koloğlu T; Çoker M; Sözmen E; Sağın FG
    Ann Clin Biochem; 2017 Sep; 54(5):539-547. PubMed ID: 27614353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of scavenger receptor class B type I polymorphisms with subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis.
    Naj AC; West M; Rich SS; Post W; Kao WH; Wasserman BA; Herrington DM; Rodriguez A
    Circ Cardiovasc Genet; 2010 Feb; 3(1):47-52. PubMed ID: 20160195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Serum Lipoprotein-Associated Phospholipase A2 and A379V Gene Polymorphisms with Carotid Plaques.
    Wu C; Zhou T; Zhou Y; Han W
    Genet Test Mol Biomarkers; 2020 Mar; 24(3):131-137. PubMed ID: 32109154
    [No Abstract]   [Full Text] [Related]  

  • 9. n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.
    Steffen BT; Steffen LM; Liang S; Tracy R; Jenny NS; Tsai MY
    Br J Nutr; 2013 Nov; 110(9):1664-71. PubMed ID: 23551952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events.
    Siddiqui MK; Smith G; St Jean P; Dawed AY; Bell S; Soto-Pedre E; Kennedy G; Carr F; Wallentin L; White H; Macphee CH; Waterworth D; Palmer CNA
    Diabetologia; 2022 Jan; 65(1):101-112. PubMed ID: 34562103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
    Wang C; Fang X; Hua Y; Liu Y; Zhang Z; Gu X; Wu X; Tang Z; Guan S; Liu H; Liu B; Guo X; Ji X
    Angiology; 2018 Jan; 69(1):49-58. PubMed ID: 28429599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review.
    Younus A; Humayun C; Ahmad R; Ogunmoroti O; Kandimalla Y; Aziz M; Malik R; Saand AR; Valdes C; Badlani R; Younus MA; Ali SS; Chen Y; Nasir K
    J Clin Lipidol; 2017; 11(2):328-337. PubMed ID: 28502488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
    Daida H; Iwase T; Yagi S; Ando H; Nakajima H
    Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte activation gene 3 and coronary artery disease.
    Golden D; Kolmakova A; Sura S; Vella AT; Manichaikul A; Wang XQ; Bielinski SJ; Taylor KD; Chen YI; Rich SS; Rodriguez A
    JCI Insight; 2016 Oct; 1(17):e88628. PubMed ID: 27777974
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?
    Ahmed MS; Ji JZ; Meng QH
    Inflamm Allergy Drug Targets; 2011 Aug; 10(4):236-46. PubMed ID: 21539512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Lp-PLA2 in lipid-lowering therapy.
    Racherla S; Arora R
    Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population.
    Ueshima H; Kadowaki T; Hisamatsu T; Fujiyoshi A; Miura K; Ohkubo T; Sekikawa A; Kadota A; Kadowaki S; Nakamura Y; Miyagawa N; Okamura T; Kita Y; Takashima N; Kashiwagi A; Maegawa H; Horie M; Yamamoto T; Kimura T; Kita T;
    Atherosclerosis; 2016 Mar; 246():141-7. PubMed ID: 26775119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis.
    Liu J; Wang W; Qi Y; Yong Q; Zhou G; Wang M; Sun J; Liu J; Jia Z; Zhao D
    J Atheroscler Thromb; 2014; 21(6):532-42. PubMed ID: 24492522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
    Hassan M
    Glob Cardiol Sci Pract; 2015; 2015():6. PubMed ID: 25830150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic invalidation of Lp-PLA
    Gregson JM; Freitag DF; Surendran P; Stitziel NO; Chowdhury R; Burgess S; Kaptoge S; Gao P; Staley JR; Willeit P; Nielsen SF; Caslake M; Trompet S; Polfus LM; Kuulasmaa K; Kontto J; Perola M; Blankenberg S; Veronesi G; Gianfagna F; Männistö S; Kimura A; Lin H; Reilly DF; Gorski M; Mijatovic V; ; Munroe PB; Ehret GB; ; Thompson A; Uria-Nickelsen M; Malarstig A; Dehghan A; ; Vogt TF; Sasaoka T; Takeuchi F; Kato N; Yamada Y; Kee F; Müller-Nurasyid M; Ferrières J; Arveiler D; Amouyel P; Salomaa V; Boerwinkle E; Thompson SG; Ford I; Wouter Jukema J; Sattar N; Packard CJ; Shafi Majumder AA; Alam DS; Deloukas P; Schunkert H; Samani NJ; Kathiresan S; ; Nordestgaard BG; Saleheen D; Howson JM; Di Angelantonio E; Butterworth AS; Danesh J;
    Eur J Prev Cardiol; 2017 Mar; 24(5):492-504. PubMed ID: 27940953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.